Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Exelixis ( (EXEL) ) has provided an announcement.
On November 4, 2025, Exelixis announced the resignation of Jeffrey Hessekiel, J.D., its Executive Vice President and General Counsel, effective in November 2025. Brenda Hefti, J.D., Ph.D., will be promoted to General Counsel, effective November 7, 2025, marking a significant leadership transition within the company.
The most recent analyst rating on (EXEL) stock is a Hold with a $40.00 price target. To see the full list of analyst forecasts on Exelixis stock, see the EXEL Stock Forecast page.
Spark’s Take on EXEL Stock
According to Spark, TipRanks’ AI Analyst, EXEL is a Outperform.
Exelixis’s strong financial performance and positive earnings call sentiment are the primary drivers of its stock score. The company’s robust revenue growth, efficient cost management, and strategic advancements in its R&D pipeline contribute to a favorable outlook. However, technical indicators suggest a bearish trend, and valuation metrics indicate fair pricing, which slightly tempers the overall score.
To see Spark’s full report on EXEL stock, click here.
More about Exelixis
Exelixis, Inc. operates in the biotechnology industry, focusing on the development of small molecule therapies for cancer treatment.
Average Trading Volume: 2,670,599
Technical Sentiment Signal: Strong Buy
Current Market Cap: $10.82B
For a thorough assessment of EXEL stock, go to TipRanks’ Stock Analysis page.